Inclusion Criteria:

- Subjects who the investigator believes that they and/or their parents or legally
acceptable representative (LAR) can and will comply with the requirements of the
protocol should be enrolled in the study.

- A female enrolled in the immunogenicity subset of study 580299-013, who received
three doses of HPV vaccine and participated in the extension study of 580299-013.

- Written informed assent obtained from the subject. For subjects below the legal age
of consent, written informed consent must be obtained from a parent or legally
acceptable representative of the subject.

Exclusion Criteria:

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product.

- Use of any investigational or non-registered product (drug or vaccine) or planned use
during the study period.

- Administration or planned administration of any HPV vaccine, other than the vaccine
administered in study 580299-013.

- Chronic administration of immunosuppressants or other immune-modifying drugs
occurring within the three months preceding study entry.

- Administration of immunoglobulins and/or any blood products occurring within the
three months preceding study entry.